Compared side by side
Orforglipron vs Semaglutide (oral): how they differ
The short answer
Both are daily GLP-1 tablets, made differently: oral semaglutide is the peptide from the weekly shot with an absorption enhancer, so only about 0.4–2% of each tablet is absorbed, while orforglipron is a small molecule (not a peptide) with 77% bioavailability that can be taken with or without food. Both are FDA-approved: oral semaglutide as Rybelsus and Ozempic tablets for type 2 diabetes and Wegovy tablets for weight management, orforglipron as Foundayo for weight management since April 2026. Commonly reported: the easy routine is orforglipron’s main draw, and the strict morning routine the hardest part of oral semaglutide.
Side by side
| Compared | Orforglipron | Semaglutide (oral) |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | Foundayo, LY3502970, Orfo | Rybelsus, Wegovy pill, Ozempic pill, Oral semaglutide |
| What it is | A GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management. | Semaglutide as a daily tablet instead of a weekly shot, FDA-approved as Rybelsus (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg) for type 2 diabetes and as Wegovy tablets (up to 25 mg) for weight management. |
| How it works | Small-molecule (non-peptide) GLP-1 receptor agonist taken as a daily tablet. Because it is a small molecule it is absorbed without the fasting and water rules of oral semaglutide: the label puts its absolute bioavailability at 77% and lets it be taken with or without food. It reduces food intake, likely by lowering appetite, and delays stomach emptying, most after the first dose; in animal studies it reached and activated brain regions that regulate appetite. FDA-approved on April 1, 2026, as Foundayo for chronic weight management, at 0.8 to 17.2 mg once daily. | The same GLP-1 receptor agonist as the weekly injection, made into a daily tablet with an absorption enhancer (SNAC). The Rybelsus and Ozempic tablet label puts absorption at about 0.4–2% of each tablet, which is why tablet doses run in whole milligrams while the weekly shot is a fraction of one. |
| Commonly reported | The easy routine is the main draw, with nausea, constipation or burping mostly in the weeks after each step-up. Its top dose averaged about 11% weight loss at 72 weeks in its main trial. | The strict morning routine is the hardest part, and nausea after each dose step feels much like the injection. Each line has its own dose steps, so log the strength on your pack. |
| Studied range | FDA label: 0.8–17.2 mg, starting dose 0.8 mg. | FDA label: 1.5–25 mg, starting dose 1.5 mg. |
| How often | Daily | Daily |
| Half-life | ~29–49 hours (FDA label; steady levels after about a week of daily tablets) | ~1 week |
| Route | Oral tablet | Oral tablet |
| Typical run | FDA-approved for long-term use alongside diet and activity. ATTAIN-MAINTAIN tested it as the follow-on to weekly injections for keeping weight off. | Not in our library |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping | Nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation |
- Category
- OrforglipronMetabolic & GLP-1
- Semaglutide (oral)Metabolic & GLP-1
- Also known as
- OrforglipronFoundayo, LY3502970, Orfo
- Semaglutide (oral)Rybelsus, Wegovy pill, Ozempic pill, Oral semaglutide
- What it is
- OrforglipronA GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management.
- Semaglutide (oral)Semaglutide as a daily tablet instead of a weekly shot, FDA-approved as Rybelsus (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg) for type 2 diabetes and as Wegovy tablets (up to 25 mg) for weight management.
- How it works
- OrforglipronSmall-molecule (non-peptide) GLP-1 receptor agonist taken as a daily tablet. Because it is a small molecule it is absorbed without the fasting and water rules of oral semaglutide: the label puts its absolute bioavailability at 77% and lets it be taken with or without food. It reduces food intake, likely by lowering appetite, and delays stomach emptying, most after the first dose; in animal studies it reached and activated brain regions that regulate appetite. FDA-approved on April 1, 2026, as Foundayo for chronic weight management, at 0.8 to 17.2 mg once daily.
- Semaglutide (oral)The same GLP-1 receptor agonist as the weekly injection, made into a daily tablet with an absorption enhancer (SNAC). The Rybelsus and Ozempic tablet label puts absorption at about 0.4–2% of each tablet, which is why tablet doses run in whole milligrams while the weekly shot is a fraction of one.
- Commonly reported
- OrforglipronThe easy routine is the main draw, with nausea, constipation or burping mostly in the weeks after each step-up. Its top dose averaged about 11% weight loss at 72 weeks in its main trial.
- Semaglutide (oral)The strict morning routine is the hardest part, and nausea after each dose step feels much like the injection. Each line has its own dose steps, so log the strength on your pack.
- Studied range
- OrforglipronFDA label: 0.8–17.2 mg, starting dose 0.8 mg.
- Semaglutide (oral)FDA label: 1.5–25 mg, starting dose 1.5 mg.
- How often
- OrforglipronDaily
- Semaglutide (oral)Daily
- Half-life
- Orforglipron~29–49 hours (FDA label; steady levels after about a week of daily tablets)
- Semaglutide (oral)~1 week
- Route
- OrforglipronOral tablet
- Semaglutide (oral)Oral tablet
- Typical run
- OrforglipronFDA-approved for long-term use alongside diet and activity. ATTAIN-MAINTAIN tested it as the follow-on to weekly injections for keeping weight off.
- Semaglutide (oral)Not in our library
- Evidence
- OrforglipronEstablished: clinical trials or FDA-approved use exists
- Semaglutide (oral)Established: clinical trials or FDA-approved use exists
- Common side effects
- OrforglipronNausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping
- Semaglutide (oral)Nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation
Typical run: Community practice — opinions vary. Not a clinical recommendation. “Not in our library” means the entry doesn’t hold it.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Orforglipron
- Day 1–30 · 0.8 mg The 0.8 mg start
- Day 31–60 · 2.5 mg 2.5 mg, the second step
- Day 61+ · 5.5 mg 5.5 mg, the first maintenance dose
- Day 91+ · 9 mg 9 mg, an optional step
- Day 121+ · 14.5 mg 14.5 mg, the step before the top
- Day 151+ · 17.2 mg 17.2 mg, the top dose
Semaglutide (oral)
Week-by-week cards for Semaglutide (oral) are not in our library.
Questions people ask
How long do orforglipron and Semaglutide (oral) last?
The half-life of orforglipron is ~29–49 hours (FDA label; steady levels after about a week of daily tablets). The half-life of Semaglutide (oral) is ~1 week.
How often are orforglipron and Semaglutide (oral) taken?
Orforglipron: daily. Route: Oral tablet. Semaglutide (oral): daily. Route: Oral tablet.
How are orforglipron and Semaglutide (oral) dosed in research?
The FDA label range for orforglipron is 0.8–17.2 mg, with a 0.8 mg starting dose. The FDA label range for Semaglutide (oral) is 1.5–25 mg, with a 1.5 mg starting dose.
What are the common side effects of orforglipron and Semaglutide (oral)?
For orforglipron, the library lists: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping. For Semaglutide (oral): nausea, abdominal pain, diarrhea, decreased appetite, vomiting, constipation.